Differences in age at diagnosis of ovarian cancer for each <i>BRCA</i> mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy-Reference-Cited by-同舟云学术

Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy

Published:2022 Issue:4 Volume:33 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Sekine Masayuki¹^ORCID,Enomoto Takayuki¹^ORCID,Arai Masami²^ORCID,Den Hiroki³^ORCID,Nomura Hiroyuki⁴^ORCID,Ikeuchi Takeshi⁵^ORCID,Nakamura Seigo⁶^ORCID,

Affiliation:

1. Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

2. Clinical Genetics, Juntendo University, Graduate School of Medicine, Tokyo, Japan.

3. Department of Hygiene, Public Health, and Preventative Medicine, Showa University School of Medicine, Tokyo, Japan.

4. Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, Toyoake, Japan.

5. Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.

6. Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan.

Publisher

Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy

Subject

Obstetrics and Gynecology,Oncology,General Medicine

Link

https://ejgo.org/pdf/10.3802/jgo.2022.33.e46

Reference25 articles.

1. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

2. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation

3. Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

4. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers

5. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reproductive outcomes in women with BRCA 1/2 germline mutations: A retrospective observational study and literature review;Open Medicine;2024-01-01

2. Risk-reducing decisions regarding germlineBRCApathogenic variant: focusing on the timing of genetic testing and RRSO;Journal of Medical Genetics;2023-12-16

3. Analysis and comparison of BRCA1/2 gene mutations in 310 cases of ovarian cancer;2023-05-25

4. The pathogenic role of the BRCA2 c.7847C>T (p.Ser2616Phe) variant in breast and ovarian cancer predisposition;Cancer Science;2023-04-17

5. Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience;Japanese Journal of Clinical Oncology;2023-03-30